Yung Zip Chemical Ind Past Earnings Performance
Past criteria checks 2/6
Yung Zip Chemical Ind has been growing earnings at an average annual rate of 35.2%, while the Pharmaceuticals industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 8.8% per year. Yung Zip Chemical Ind's return on equity is 9.4%, and it has net margins of 11.2%.
Key information
35.2%
Earnings growth rate
35.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 18.5% |
| Revenue growth rate | 8.8% |
| Return on equity | 9.4% |
| Net Margin | 11.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly
Apr 29
Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?
Mar 04Yung Zip Chemical Ind (GTSM:4102) Seems To Use Debt Quite Sensibly
Jan 28
Are Yung Zip Chemical Ind's (GTSM:4102) Statutory Earnings A Good Guide To Its Underlying Profitability?
Dec 22Should Weakness in Yung Zip Chemical Ind. Co., Ltd.'s (GTSM:4102) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Nov 25Revenue & Expenses BreakdownBeta
How Yung Zip Chemical Ind makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 559 | 63 | 84 | 34 |
| 30 Sep 23 | 588 | 67 | 84 | 35 |
| 30 Jun 23 | 577 | 59 | 83 | 35 |
| 31 Mar 23 | 595 | 83 | 83 | 35 |
| 31 Dec 22 | 567 | 70 | 81 | 35 |
| 30 Sep 22 | 533 | 51 | 75 | 33 |
| 30 Jun 22 | 496 | 35 | 71 | 32 |
| 31 Mar 22 | 478 | 14 | 67 | 32 |
| 31 Dec 21 | 478 | 6 | 66 | 31 |
| 30 Sep 21 | 460 | 12 | 69 | 33 |
| 30 Jun 21 | 483 | 13 | 71 | 35 |
| 31 Mar 21 | 466 | 10 | 74 | 34 |
| 31 Dec 20 | 463 | 31 | 73 | 33 |
| 30 Sep 20 | 439 | 30 | 71 | 33 |
| 30 Jun 20 | 427 | 39 | 68 | 31 |
| 31 Mar 20 | 419 | 42 | 65 | 31 |
| 31 Dec 19 | 417 | 31 | 64 | 31 |
| 30 Sep 19 | 429 | 26 | 62 | 29 |
| 30 Jun 19 | 422 | 16 | 60 | 28 |
| 31 Mar 19 | 389 | -2 | 58 | 27 |
| 31 Dec 18 | 357 | -15 | 56 | 26 |
| 30 Sep 18 | 324 | -12 | 57 | 26 |
| 30 Jun 18 | 311 | -11 | 56 | 25 |
| 31 Mar 18 | 312 | -18 | 58 | 24 |
| 31 Dec 17 | 314 | -25 | 59 | 24 |
| 30 Sep 17 | 301 | -38 | 54 | 22 |
| 30 Jun 17 | 279 | -64 | 54 | 22 |
| 31 Mar 17 | 280 | -69 | 51 | 23 |
| 31 Dec 16 | 268 | -68 | 50 | 22 |
| 30 Sep 16 | 285 | -63 | 52 | 24 |
| 30 Jun 16 | 306 | -28 | 52 | 25 |
| 31 Mar 16 | 312 | -20 | 52 | 28 |
| 31 Dec 15 | 318 | -28 | 54 | 28 |
| 30 Sep 15 | 307 | -38 | 53 | 28 |
| 30 Jun 15 | 299 | -50 | 53 | 27 |
| 31 Mar 15 | 285 | -62 | 53 | 25 |
| 31 Dec 14 | 277 | -66 | 52 | 25 |
| 30 Sep 14 | 285 | -65 | 53 | 27 |
| 30 Jun 14 | 278 | -102 | 53 | 28 |
| 31 Mar 14 | 278 | -87 | 54 | 28 |
| 31 Dec 13 | 300 | -67 | 55 | 31 |
| 30 Sep 13 | 298 | -59 | 54 | 37 |
| 30 Jun 13 | 332 | -18 | 58 | 38 |
Quality Earnings: 4102 has high quality earnings.
Growing Profit Margin: 4102's current net profit margins (11.2%) are lower than last year (12.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4102 has become profitable over the past 5 years, growing earnings by 35.2% per year.
Accelerating Growth: 4102's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 4102 had negative earnings growth (-10.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-15%).
Return on Equity
High ROE: 4102's Return on Equity (9.4%) is considered low.